论文部分内容阅读
目的:探讨卡培他滨联合奥沙利铂治疗晚期结直肠癌患者的临床疗效及对患者生活质量的影响。方法:选取我院2013年3月-2015年12月收治的40例晚期结直肠癌患者,按乱数表法分为观察组和对照组各20例。对照组给予卡培他滨治疗,观察组给予卡培他滨联合奥沙利铂治疗,两组均治疗3周期。对比两组患者治疗后4周的客观缓解率和临床受益率,对比两组患者治疗前、治疗后4周的功能状态评分(KPS)和体力状况评分(ZPS),对比两组患者6个月、1年生存率以及并发症发生率。结果:治疗后4周观察组临床受益率和客观缓解率显著高于对照组,差异有统计学意义(P<0.05);与治疗前相比,治疗后4周两组KPS评分显著升高,ZPS评分显著降低,差异均有统计学意义(P<0.05);与对照组相比,治疗后4周观察组KPS评分显著升高,ZPS评分显著降低,差异均有统计学意义(P<0.05);两组患者在治疗过程中恶心呕吐、口腔黏膜炎、贫血、血小板减少、白细胞减少、腹泻等并发症发生率比较差异均无统计学意义(P>0.05);观察组1年生存率显著高于对照组,差异有统计学意义(P<0.05)。结论:卡培他滨联合奥沙利铂治疗晚期结直肠癌患者疗效较好,能提高患者的客观缓解率、临床受益率、生活质量和1年生存率,较单用卡培他滨治疗优势明显,值得临床推广。
Objective: To investigate the clinical efficacy of capecitabine combined with oxaliplatin in patients with advanced colorectal cancer and its impact on quality of life. Methods: Forty patients with advanced colorectal cancer who were treated in our hospital from March 2013 to December 2015 were selected and randomly divided into observation group (20 cases) and control group (20 cases). The control group received capecitabine, and the observation group received capecitabine plus oxaliplatin. Both groups were treated for 3 cycles. The objective response rate and clinical benefit rate were compared between the two groups after 4 weeks of treatment. The scores of KPS and ZPS before treatment and 4 weeks after treatment were compared between the two groups, 6 months , 1-year survival rate and complication rate. Results: After 4 weeks of treatment, the clinical benefit rate and objective remission rate of the observation group were significantly higher than those of the control group (P <0.05). Compared with those before treatment, the KPS scores of the two groups were significantly increased at 4 weeks after treatment, (P <0.05). Compared with the control group, the KPS score of the observation group was significantly increased and the ZPS score was significantly lower at 4 weeks after treatment (P <0.05), and the differences were statistically significant ). There was no significant difference in the incidence of complications such as nausea and vomiting, oral mucositis, anemia, thrombocytopenia, leucopenia and diarrhea between the two groups (P> 0.05). The 1-year survival rate of the observation group was significantly Higher than the control group, the difference was statistically significant (P <0.05). Conclusion: Capecitabine combined with oxaliplatin is effective in treating patients with advanced colorectal cancer, which can improve the objective response rate, clinical benefit rate, quality of life and 1-year survival rate compared with capecitabine alone Obviously, it is worth clinical promotion.